CU24303B1 - Compuesto de benzotiazolona - Google Patents

Compuesto de benzotiazolona

Info

Publication number
CU24303B1
CU24303B1 CUP2014000028A CU20140028A CU24303B1 CU 24303 B1 CU24303 B1 CU 24303B1 CU P2014000028 A CUP2014000028 A CU P2014000028A CU 20140028 A CU20140028 A CU 20140028A CU 24303 B1 CU24303 B1 CU 24303B1
Authority
CU
Cuba
Prior art keywords
benzotiazolona
composite
formula
sarcopenia
disuse
Prior art date
Application number
CUP2014000028A
Other languages
English (en)
Other versions
CU20140028A7 (es
Inventor
Jun Cao
Bernhard Erb
Robin Alec Fairhurst
Arnaud Grandeury
Shinji Hatakeyama
Holbro Magdalena Koziczak-
Xinzhong Lai
Philipp Lustenberger
Bernd Riebesehl
Nicola Tufilli
Thomas Ullrich
Xiang Wu
Jianguang Zhou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47010668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24303(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20140028A7 publication Critical patent/CU20140028A7/es
Publication of CU24303B1 publication Critical patent/CU24303B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención proporciona un compuesto de la fórmula (I) en forma libre o en forma de sal farmacéuticamente aceptable que es (R)-7-(2-((1-(4-butoxifenil)-2-metilpropan-2-il)amino)-1-hidroxietil)-5-hidroxibenzo[d] tiazol-2(3H)-ona,</p> <p>ESPACIO PARA FÓRMULA</p> <p>activo como agonista del receptor adrenérgico y útil en el tratamiento o prevención de la distrofia muscular, atrofia relacionada con el desuso, caquexia o sarcopenia.</p>
CUP2014000028A 2011-09-06 2012-09-05 Compuesto de benzotiazolona CU24303B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011079379 2011-09-06
PCT/IB2012/054580 WO2013035047A1 (en) 2011-09-06 2012-09-05 Benzothiazolone compound

Publications (2)

Publication Number Publication Date
CU20140028A7 CU20140028A7 (es) 2014-05-27
CU24303B1 true CU24303B1 (es) 2018-01-10

Family

ID=47010668

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000028A CU24303B1 (es) 2011-09-06 2012-09-05 Compuesto de benzotiazolona

Country Status (39)

Country Link
US (6) US8933108B2 (es)
EP (1) EP2753609B1 (es)
JP (2) JP6130835B2 (es)
KR (2) KR101800140B1 (es)
CN (2) CN103781771B (es)
AP (1) AP3830A (es)
AR (1) AR087787A1 (es)
AU (1) AU2013200422C1 (es)
BR (1) BR112014004732A2 (es)
CA (1) CA2845766A1 (es)
CL (1) CL2014000493A1 (es)
CO (1) CO6900147A2 (es)
CR (1) CR20140114A (es)
CU (1) CU24303B1 (es)
CY (1) CY1118585T1 (es)
DK (1) DK2753609T3 (es)
EA (1) EA022909B1 (es)
ES (1) ES2615052T3 (es)
GT (1) GT201400042A (es)
HR (1) HRP20170075T1 (es)
HU (1) HUE030530T2 (es)
IL (1) IL231235A (es)
JO (1) JO3192B1 (es)
LT (1) LT2753609T (es)
MX (1) MX345405B (es)
MY (1) MY163301A (es)
PE (1) PE20141993A1 (es)
PH (1) PH12014500399A1 (es)
PL (1) PL2753609T3 (es)
PT (1) PT2753609T (es)
RS (1) RS55468B1 (es)
SG (1) SG2014013114A (es)
SI (1) SI2753609T1 (es)
TN (1) TN2014000060A1 (es)
TW (1) TWI555738B (es)
UA (1) UA114295C2 (es)
UY (1) UY34312A (es)
WO (1) WO2013035047A1 (es)
ZA (2) ZA201401112B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
DK2890687T3 (en) * 2012-08-30 2017-10-09 Novartis Ag Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
EP2961391B1 (en) * 2013-02-28 2017-05-17 Novartis AG Formulation comprising benzothiazolone compound
US10967119B1 (en) 2019-04-01 2021-04-06 Azizi Bilal Wearable medication injecting device

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308157B1 (en) * 1987-09-15 1997-02-26 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
US20070082918A1 (en) * 1993-11-02 2007-04-12 Naftchi N E Neurologically active compounds and compounds with multiple activities
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1999009018A1 (en) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY
EP1144387A1 (en) 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
JP2006521201A (ja) * 2003-03-26 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 鏡像異性体富化したアルコール類およびアミン類を製造する方法
WO2004087142A1 (en) * 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
JP2007503472A (ja) * 2003-06-10 2007-02-22 カリプシス・インコーポレーテッド 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物
AU2004247136A1 (en) 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
JP2009513531A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
JP2009514779A (ja) 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
GB0402797D0 (en) * 2004-02-09 2004-03-10 Novartis Ag Organic compounds
CA2565243A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
WO2006014704A1 (en) 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
WO2007086078A2 (en) 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
MX2008010187A (es) 2006-02-10 2008-10-31 Summit Corp Plc Tratamiento de distrofia muscular de duchenne.
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2064174B1 (en) * 2006-08-10 2016-10-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) 2008-12-18 2009-01-28 Astrazeneca Ab New combination
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
DK2890687T3 (en) * 2012-08-30 2017-10-09 Novartis Ag Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
EP2961391B1 (en) 2013-02-28 2017-05-17 Novartis AG Formulation comprising benzothiazolone compound

Also Published As

Publication number Publication date
CL2014000493A1 (es) 2014-10-03
LT2753609T (lt) 2017-01-10
CN106187942B (zh) 2020-06-26
IL231235A (en) 2017-09-28
DK2753609T3 (en) 2017-02-06
HUE030530T2 (en) 2017-05-29
US10251868B2 (en) 2019-04-09
JP2017132781A (ja) 2017-08-03
EP2753609A1 (en) 2014-07-16
TWI555738B (zh) 2016-11-01
AR087787A1 (es) 2014-04-16
JP6130835B2 (ja) 2017-05-17
US20180140582A1 (en) 2018-05-24
JO3192B1 (ar) 2018-03-08
CN103781771B (zh) 2016-08-24
KR101628585B1 (ko) 2016-06-08
CR20140114A (es) 2014-05-06
JP2014525472A (ja) 2014-09-29
UA114295C2 (uk) 2017-05-25
ES2615052T3 (es) 2017-06-05
PH12014500399A1 (en) 2021-06-02
JP6340103B2 (ja) 2018-06-06
US20160075670A1 (en) 2016-03-17
EA201490573A1 (ru) 2014-06-30
UY34312A (es) 2013-04-30
AU2013200422A1 (en) 2013-03-21
US20150094346A1 (en) 2015-04-02
IL231235A0 (en) 2014-04-30
US20160279107A1 (en) 2016-09-29
US9913828B2 (en) 2018-03-13
AU2013200422B2 (en) 2014-08-07
CU20140028A7 (es) 2014-05-27
AP3830A (en) 2016-09-30
EA022909B1 (ru) 2016-03-31
KR20140057382A (ko) 2014-05-12
ZA201500790B (en) 2017-04-26
US8933108B2 (en) 2015-01-13
KR20160038079A (ko) 2016-04-06
RS55468B1 (sr) 2017-04-28
PE20141993A1 (es) 2014-12-17
PT2753609T (pt) 2017-02-08
GT201400042A (es) 2015-02-19
NZ621089A (en) 2015-07-31
MX2014002688A (es) 2014-04-14
CA2845766A1 (en) 2013-03-14
AU2013200422C1 (en) 2015-01-15
SG2014013114A (en) 2014-07-30
CN106187942A (zh) 2016-12-07
TW201317221A (zh) 2013-05-01
HRP20170075T1 (hr) 2017-03-24
CY1118585T1 (el) 2017-07-12
KR101800140B1 (ko) 2017-11-21
BR112014004732A2 (pt) 2017-03-28
US20150336914A1 (en) 2015-11-26
MX345405B (es) 2017-01-30
PL2753609T3 (pl) 2017-05-31
WO2013035047A1 (en) 2013-03-14
US20130245080A1 (en) 2013-09-19
AP2014007462A0 (en) 2014-02-28
ZA201401112B (en) 2016-01-27
CN103781771A (zh) 2014-05-07
TN2014000060A1 (en) 2015-07-01
CO6900147A2 (es) 2014-03-20
EP2753609B1 (en) 2016-11-09
SI2753609T1 (sl) 2017-03-31
MY163301A (en) 2017-09-15

Similar Documents

Publication Publication Date Title
CU24303B1 (es) Compuesto de benzotiazolona
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
PE20142285A1 (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria
AU2012214029A8 (en) Rorgammat inhibitors
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX385616B (es) Inhibidores de cdk
IN2015DN00185A (es)
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
MY155212A (en) Quaternary ammonium salt compounds
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
BR112012018955A2 (pt) combinação para administração simultânea, separada ou sequencial e ligante sigma ou um sal, isômero, pró-droga ou solvato farmaceuticamente aceitável do mesmo
AP3521A (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors
EA201390499A1 (ru) Соединения, подходящие для ингибирования снк1
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
UY33495A (es) Derivados de bisaril (tio)morfolina como moduladores s1p
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол
PH12014501215A1 (en) Peptide deformylase inhibitors
ES1072101Y (es) Protector para envases, en especial para envases de tipo lata
UY32991A (es) Derivados de dihidro pirroloquinolina
SA515360076B1 (ar) أملاح من مركب البنزوثيازولون الذي يكون مقاوم لمستقبل أدريني بيتا-2